Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.79 |
| ▸ | CNR1 | P21554 | 7/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3390684 | 0.99 | CNR2 (0.78) | CNR2CNR1HTR1ATAOK3P2RX7 | |
| SCHEMBL4120174 | 0.89 | CNR2 (1.00) | CNR2CNR1TAOK3DRD2 | |
| SCHEMBL737219 | 0.89 | CNR2 (1.00) | CNR2CNR1TAOK3DRD2 | |
| Hydrochloric Acid SCHEMBL3390668 | 0.88 | CNR2 (0.98) | CNR2CNR1TAOK3DRD2 | |
| Hydrochloric Acid SCHEMBL3393278 | 0.88 | CNR2 (0.98) | CNR2CNR1TAOK3DRD2 | |
| SCHEMBL762167 | 0.83 | CNR2 (0.79) | CNR2CNR1TAOK3DRD2LMNA | |
| SCHEMBL737884 | 0.83 | CNR2 (0.89) | CNR2CNR1 | |
| SCHEMBL737649 | 0.83 | CNR2 (0.89) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL3386627 | 0.83 | CNR2 (0.78) | CNR2CNR1TAOK3DRD2LMNA | |
| SCHEMBL762507 | 0.82 | CNR2 (0.87) | CNR2CNR1HTR1ADRD2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1861377-B1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885HTR1A 142/4885 |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885HTR1A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.